Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Shield Therapeutics ( (GB:STX) ) has issued an update.
Shield Therapeutics announced the grant of share options to its new CEO, Anders Lundstrom, under its Retention and Performance Share Plan. This move is part of Lundstrom’s onboarding process, providing him with options over 5,000,000 ordinary shares, equivalent to approximately 0.5% of the total AIM securities in issue. The grant aims to align leadership incentives with the company’s long-term goals and is expected to reinforce the company’s strategic positioning in the iron deficiency treatment market.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial stage specialty pharmaceutical company focusing on addressing iron deficiency through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). This product addresses a significant unmet need for patients with iron deficiency, with or without anemia. Shield has launched ACCRUFeR® in the U.S. with Viatris Inc. and has licensing agreements with several companies for its commercialization in Europe, Asia, and Canada.
YTD Price Performance: 37.04%
Average Trading Volume: 2,933,324
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £36.46M
See more insights into STX stock on TipRanks’ Stock Analysis page.
